Revlimid Therapy May Delay Myeloma Progression and Increase Survival
Revlimid (lenalidomide) therapy maintenance has been shown to delay disease progression and extend survival in newly diagnosed multiple myeloma (NDMM) patients who receive a transplant of their own blood-forming stem cells, called autologous stem-cell transplantation (ASCT). The findings include data of 1,208 NDMM patients and were reported in a study…